Ponezumab
From Infogalactic: the planetary knowledge core
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | beta-amyloid |
| Identifiers | |
| CAS Number | 1178862-65-1  |
| ATC code | none |
| UNII | 1TG15H1XE9  |
| Chemical data | |
| Formula | C6552H10158N1730O2090S52 |
| Molecular mass | 148.3 kg/mol |
| (what is this?) (verify) |
|
Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.[1]
Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.[2] Detailed reports have to be released.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Pfizer products
- Treatments and potential treatments for Alzheimer's
- Monoclonal antibody stubs
- Nervous system drug stubs
